Trial Profile
Open label, pilot phase II study of Glivec in children and adolescents with life threatening diseases known to be associated with one or more Glivec-sensitive tyrosine kinases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 29 Oct 2005 New trial record.